GENEOS THERAPEUTICS
Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease.
GENEOS THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2016-08-01
Address:
Plymouth Meeting, Pennsylvania, United States
Country:
United States
Website Url:
http://www.geneostx.com
Total Employee:
1+
Status:
Active
Total Funding:
39.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Acylin Therapeutics
Acylin Therapeutics operates in the pharmaceutical and drug manufacturing industry developing inhibitors of cellular acetylation.
Amyloid Solution
Amyloid Solution is a developer of therapy intended to overcome Alzheimer by developing modifying treatments.
Atom Bioworks
Atom Bioworks is a developer of a pattern-recognition enabled sensing and therapeutics platform designed to help in medical.
Carrick Therapeutics
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Dignify Therapeutics
Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal.
Dracen Pharmaceuticals
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
Edifice Health
Edifice Health is a immunological health and personalized nutrition company offering a novel metric of inflammatory health.
GenFleet Therapeutics
GenFleet Therapeutics is a biotechnology developer and researcher of molecular pharmaceuticals targeting cancer treatments.
Hale Therapeutics
Hale Therapeutics, a Philadelphia firm developing a nicotine vaporizer designed to wean smokers and vapers off of nicotine.
Hoba Therapeutics
Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Manifold Bio
Manifold Bio is building a protein barcoding platform to bring the power of multiplexed measurement.
Marker Therapeutics
Marker Therapeutics is a clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
MDI Therapeutics
MDI Therapeutics is a operator of an discovery stage company focused on developing novel therapies for fibrotic diseases.
VYNE Therapeutics
VYNE Therapeutics is a clinical late-stage biopharmaceutical company developing treatments associated with dermatologic conditions.
Mimosa Therapeutics
Mimosa Therapeutics is a biotech company that offers research-grade natural products and drug potency test kits.
Nivien Therapeutics
Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.
Novita Pharmaceuticals
Novita Pharmaceuticals is a developer of therapeutic drugs for the treatment of cancer.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Opsonix
Opsonix is a developer of a pathogen-extracting therapy designed to transform the treatment of bloodstream infections and sepsis.
Oxford Vacmedix
Develop therapeutic agents for the treatment of cancer .
Palleon Pharmaceuticals
Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.
PDC*line Pharma
PDC*line Pharma develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells.
Pear Therapeutics
Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Phico Therapeutics
Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
PolyProx
PolyProx Therapeutics is a developer of a novel class of drug intended to provide new therapies for cancer treatment.
Providence Therapeutics
Providence Therapeutics is a biotechnology company that develops a personalized mRNA cancer vaccine designed to treat ovarian cancer.
PuREC
PuREC is a developer of a culture technology intended to bring efficacy to the treatment process.
Pyxis Oncology
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Qool Therapeutics
Qool Therapeutics is dedicated to creating non-invasive, efficient temperature management therapies to preserve cells.
Repare Therapeutics
Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.
Rodeo Therapeutics
Rodeo Therapeutics is a developer of small-molecule therapies designed to promote regeneration and repair of multiple tissue types.
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Skyhawk Therapeutics
Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.
Stellanova Therapeutics
Stellanova Therapeutics is a private, development-stage biotechnology company that focuses on cancer therapies
Stemgenics
Stemgenics is a developer of a technology that converts mature skin cells into personalized stem cells.
USMD
USMD Holdings develops, operates and manages entities that deliver diagnostic, therapeutic and hospital-based health care to patients.
Westlake Therapeutics
The company is committed to the development of a variety of innovative cell therapy products for rare diseases, cancer, etc.
ZY Therapeutics
ZY Therapeutics develops a drug delivery platform for cancer therapeutics using nanotechnology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Global Bio Fund
Global Bio Fund investment in Series A - Geneos Therapeutics
Flerie Invest
Flerie Invest investment in Series A - Geneos Therapeutics
Sante Ventures
Sante Ventures investment in Series A - Geneos Therapeutics
Korea Investment Partners
Korea Investment Partners investment in Series A - Geneos Therapeutics
Inovio Pharmaceuticals
Inovio Pharmaceuticals investment in Series A - Geneos Therapeutics
Sante Ventures
Sante Ventures investment in Series A - Geneos Therapeutics
Inovio Pharmaceuticals
Inovio Pharmaceuticals investment in Series A - Geneos Therapeutics
Korea Investment Partners
Korea Investment Partners investment in Series A - Geneos Therapeutics
Sante Ventures
Sante Ventures investment in Series A - Geneos Therapeutics
Inovio Pharmaceuticals
Inovio Pharmaceuticals investment in Series A - Geneos Therapeutics
Official Site Inspections
http://www.geneostx.com Semrush global rank: 7.27 M Semrush visits lastest month: 548
- Host name: al-web-pro-02.aplusl.io
- IP address: 3.214.35.33
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Geneos Therapeutics"
Team Archive - Geneos Therapeutics
Joann Peters joined Geneos after a successful 19-year career working in the Contract Research Organization (CRO) industry where she supported the growth strategy of companies and effectively led oncology focused study teams.See details»
Geneos Therapeutics - LinkedIn
Geneos Therapeutics | 2,016 followers on LinkedIn. Developing the next generation of patient specific neoantigen-targeting cancer immunotherapies, one patient at a time. | At Geneos, our passion ...See details»
Geneos Therapeutics - Crunchbase Company Profile
Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop …See details»
Geneos Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Www.geneostx.com. Startups | Holding Company | 2016 | Pennsylvania, United States | < 10 | www.geneostx.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational …See details»
Geneos Therapeutics - Overview, News & Similar companies
Mar 6, 2024 View Geneos Therapeutics (www.geneostx.com) location in Pennsylvania, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Geneos Therapeutics - VentureRadar
"At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment. Our passion is to develop personalized therapies to unleash the most powerful …See details»
CORPORATE OVERVIEW 1Q 2021 - Geneos Therapeutics
Mar 4, 2021 8 • Mutations and other somatic changes in the tumor (cancer neoantigens)are recognized by the immune system as “foreign” to mount an immune response against the …See details»
Exquisitely personalized cancer immunotherapies - Nature
Www.geneostx.com Exquisitely personalized cancer immunotherapies Pennsylvania-based Geneos Therapeutics is using its clinically validated GT-EPIC platform to generate cancer …See details»
Geneos Therapeutics - Craft
Geneos Therapeutics has 1 employees at their 1 location and $22.5 m in total funding,. See insights on Geneos Therapeutics including office locations, competitors, revenue, financials, …See details»
Geneos Therapeutics Secures $12 Million in Series A1 Financing to ...
Mar 3, 2021 For more information about the company and its leadership team, visit www.geneostx.com. About Geneos Therapeutics . At Geneos Therapeutics, we believe that …See details»
NEWS RELEASE Immediate Release Geneos Therapeutics …
[email protected] * * * This press release contains certain forward-looking statements relating to our business, including our plans regarding the development of tumor neoantigen …See details»
Geneos Therapeutics Announces Positive Phase 1/2 Data for GT …
Apr 7, 2024 The ORR for GT-30 is currently at 30.6% (11/36), including three complete responses (CR) and eight partial responses. This response is statistically significant based on …See details»
VGXI and Geneos Therapeutics Expand Partnership for …
Mar 16, 2021 Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. Expand their Clinical Manufacturing Supply Agreement in Support of Geneos’ Ongoing GT-30 …See details»
Geneos Therapeutics Announces Positive Clinical Data for …
Nov 7, 2022 For more information, please visit www.geneostx.com. This press release contains certain forward-looking statements relating to our business, including our plans regarding the …See details»
Reported the first clinical efficacy data for our lead program (GT …
Ph: 267-440-4232; Web: www.geneostx.com . Dear Geneos stakeholder s and well-wishers, Geneos Therapeutics turns 3 years old on February 21, 2022. I couldn’t be more excited and …See details»
Geneos Therapeutics Announces Another Complete Response in …
Dec 14, 2022 Geneos Therapeutics, a privately held, clinical stage biotherapeutics company, believes that the company's personalized therapeutic cancer vaccines (PTCVs) may serve an …See details»
Immediate Release Geneos Therapeutics Secures $12 Million in …
Mar 3, 2021 www.geneostx.com . About Geneos Therapeutics . At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment. Our passion is to …See details»
Geneos Therapeutics Announces First Patient Dosed with its DNA …
Jul 10, 2019 Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology This is the First-in-Human …See details»
VGXI and Geneos Therapeutics Expand Partnership for Personalized
Mar 16, 2021 Page3/3 Ifyouhaveanyquestionsregardinginformationinthesepressreleasespleasecontactthecompanylistedinthepressrelease.Ourcompletedisclaimer …See details»